Form 4: Serina Therapeutics Director Gregory Bailey Acquires Shares in Open Market Transaction

Director Gregory Bailey of Serina Therapeutics acquired 3,866 shares of common stock in a series of open market transactions.

Summary

• Gregory Bailey, a director at Serina Therapeutics, purchased 3,866 shares of the company's common stock on December 17, 2024.
• The shares were acquired through multiple transactions at a weighted average price of $4.5899 per share.
• The price per share ranged from a low of $4.54 to a high of $4.74.
• Following the transaction, Mr. Bailey directly owns 67,243 shares of Serina Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive as a director purchasing shares is generally seen as a positive sign, but it's a routine transaction.

Positives

• The director's purchase of shares indicates confidence in the company's future prospects.
• The open market purchase suggests a genuine belief in the company's value.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The transaction is typical for directors who may buy or sell shares in their company.

Stakeholder Impact

• The purchase may have a slightly positive impact on shareholder sentiment, as it indicates confidence from a company director.

Key Dates

Keywords

Serina Therapeutics, Gregory Bailey, stock purchase, insider trading, Form 4, director, common stock, open market